Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod versus intramuscular interferon beta-1a in pediatric relapsing multiple sclerosis
2011-005677-23Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate. Started Feb 2013; status: terminated.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2011-005677-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005677-23.